[Screening and identifying of erythrocyte alloantibodies in patients with Thalassemia major referred to Ahvaz Shafa hospital]

Patients with thalassemia major are clinically dependent on red blood cell [RBC] transfusions. Performing multiple transfusions increase the risk of transfusion-related complications including blood-borne infections, iron overload and also RBC alloimmunization. This cross-sectional descriptive study was conducted on 70 thalassemia cases with regular blood transfusions. The serum samples were screened for the detection of the unexpected antibodies and the positive samples were subjected to antibody identification. Among 70 cases, 6 [8.6%] were identified as unexpected alloantibody; three cases as Anti-K, one as Anti-E and another one as Anti-D. Coincidence of Anti D and Anti-E was detected in one case. Eighteen patients [25.7%] were splenectomized. No significant correlation was seen between the presence of alloantibody and age, sex, the time of first transfusion and spleen condition. Considering that the most prevalent unexpected antibodies [8.6%] identified in this study were against the Kell and Rh system antigens, the evaluation of compatibility for antigens found can be recommended before the performing of transfusion. Therefore, this strategy may decrease the possibility of recipient immunization and production of the unexpected antibodies against donor RBCs

Transfusion transmitted virus [TTV] infection in thalassemic patients

TTV was first isolated from the serum of a Japanese patient with post transfusion hepatitis of unknown etiology in 1977. TTV has been visualized by electron microscopy and was found to be an unenveloped, small, spherical particle with a diameter of 30-32 nm, and is a member of family related to Circovridae family. The exact role of TTV in the pathogenesis of liver disease is yet to be established. Our aim was to determine the prevalence of TTV in thalassemic patients in Ahwaz. Viral DNA was studied in 250 thalasemic patients. The results were compared with those of 250 blood donor controls. DNA was extracted from plasma and amplified by semi nested polymerase chain reaction with reported primer sets from a conserved region of the TTV genome. 57.2% [143/250] samples obtained from patients and 20% [54/250] of blood donors were positive for TTV-DNA detected by PCR. The difference in TTV prevalence between the two groups was statistically [CHI 2] significant [P= 0.0001]. The prevalence of TTV-DNA in Iranian thalassemic patients is high, which is the same as other countries